Verge Labs

¿Qué es Verge Labs?

Verge Labs offers CONVERGE, an AI platform for neuroscience drug development. It combines foundation models with systems-biology workflows and proprietary multimodal CNS patient data to help drug developers investigate targets, test program decisions against human biology, and plan clinical trials by molecular patient subgroup.

Its first model, vBx-1.0, is being previewed through CONVERGE with partner drug developers. Collaborations are underway to validate its performance on partners’ clinical-trial datasets. Verge says it infers brain molecular state from accessible patient inputs such as blood, imaging and clinical attributes, which it describes as a virtual biopsy. Drug developers can engage with CONVERGE through a full target-discovery campaign or a focused human-relevance assessment for a single asset.

¿Qué puede hacer Verge Labs?

Target discovery from human disease biology

CONVERGE analyzes multimodal patient data to surface causal disease signatures and candidate genes that may shift a patient’s brain state toward health when modulated.

Program decisions tested against patient data

Teams can examine target pathways across patient subgroups and assess whether preclinical models reflect the human biology relevant to a development program.

Molecular patient stratification

For clinical-trial planning, CONVERGE groups populations by molecular endotype and identifies subgroups likely to benefit and pharmacodynamic biomarkers that may move early.

vBx-1.0 virtual biopsy

Verge is previewing vBx-1.0 through CONVERGE with partner drug developers. Collaborations are underway to validate its performance on partners’ clinical-trial datasets. Verge says the model reads out molecular brain state from accessible modalities such as blood, imaging and clinical attributes, producing what it calls a virtual biopsy; the model can be fine-tuned with program- and trial-specific data.

Commercial research engagements

Drug developers can engage Verge for a full target-discovery campaign or a focused human-relevance assessment of a single asset.

Casos de uso

“Explore targets for a CNS program”

Use human disease biology to investigate candidate genes and pathways for a neuroscience drug-development program.

“Choose translational models and indications”

Assess how a target behaves across patient subgroups and whether a preclinical model reflects the patient biology a program aims to address.

“Plan biomarker-led clinical trials”

Identify molecular subgroups for enrollment and biomarkers to track in an investigational CNS study.

Preguntas frecuentes

What is CONVERGE?

CONVERGE is Verge Labs’ AI platform for neuroscience drug development. It combines foundation models and systems-biology workflows for target discovery, program assessment and clinical-trial planning.

What does vBx-1.0 do?

Verge is previewing vBx-1.0 through CONVERGE with partner drug developers. Collaborations are underway to validate its performance on partners’ clinical-trial datasets.

What drug-development work can the platform support?

Verge describes workflows for discovering CNS targets, testing program decisions against human patient data, stratifying trial populations by molecular endotype and identifying biomarkers.

How can a drug developer work with Verge?

The company lists engagements ranging from a full target-discovery campaign to a focused human-relevance assessment for a single asset. Contact Verge to discuss a project and its scope.